Subscribe to Updates

    Get the latest news from Legacy Medi4!

    Our Picks

    What Is Oil Pulling?

    July 19, 2023

    Top Sweetener Officially Declared a Carcinogen

    July 14, 2023

    Disturbing New Finding Links Cognitive Decline to Dental Hygiene : ScienceAlert

    July 8, 2023

    When the Woods Get Noisy, the Animals Get Nervous

    July 8, 2023
    Facebook Twitter Instagram
    • Privacy Policy
    • Contact Us
    • About Us
    • Disclaimer
    Facebook Twitter Instagram YouTube
    Legacy Medi4Legacy Medi4
    • World News
    • Business
    • Entertainment
    • Health
    • Science
    • Sports
    • Technology
    Legacy Medi4Legacy Medi4
    Home»Business»Pfizer, BioNTech start trial of next-gen COVID-19 vaccine for broader protection
    Business

    Pfizer, BioNTech start trial of next-gen COVID-19 vaccine for broader protection

    Todd LivingstonBy Todd LivingstonNovember 17, 2022No Comments2 Mins Read
    Share
    Facebook Twitter LinkedIn Pinterest Email

    Row of bottles for the Coronavirus vaccine.  Depth of field.

    -slav-

    Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) said they initiated a phase 1 trial of a next-generation COVID-19 vaccine aimed at boosting SARS-CoV-2 T cell responses and enhancing immunity to COVID-19.

    The candidate, BNT162b4, has T cells antigen mRNA encoding of novel coronavirus non-spike proteins that are highly conserved among many strains of SARS-CoV-2 and will be evaluated together with the company’s Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine.

    The companies added that the non-spike protein was selected based on BioNTech’s priorities and was developed as a vaccine candidate with the goal of enhancing T-cell immunity and increasing the persistence of immunity against COVID.

    BNT162b4 will be evaluated in a US trial enrolling ~180 healthy people between the ages of 18 and 55 years, who have received at least three doses of the mRNA-based COVID-19 vaccine.

    The pilot study will investigate different dose levels of BNT162b4 given in combination with 30-µg of the company’s Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine and will be compared to the 30-µg administration. dose of Omicron BA.4/BA.5-adapted bivalent COVID vaccine as booster.

    The research is part of the company’s efforts to develop multiple vaccines with the goal of providing a potential vaccine against COVID-19.

    BNTX +0.60% to $165.89 premarket Nov. 17

    Source link

    Share. Facebook Twitter Pinterest LinkedIn WhatsApp Reddit Tumblr Email
    Todd Livingston

    Related Posts

    Corsair Gaming bumps 3% as holiday quarter tops forecasts (NASDAQ:CRSR)

    February 9, 2023

    META has rallied more than 40% so far in 2023. Is it still a buy here?

    February 9, 2023

    Analysts stay positive on Google AI after historic value wipeout (NASDAQ:GOOGL)

    February 9, 2023

    Leave A Reply Cancel Reply

    Our Picks

    What Is Oil Pulling?

    July 19, 2023

    Top Sweetener Officially Declared a Carcinogen

    July 14, 2023

    Disturbing New Finding Links Cognitive Decline to Dental Hygiene : ScienceAlert

    July 8, 2023

    When the Woods Get Noisy, the Animals Get Nervous

    July 8, 2023

    Subscribe to Updates

    Get the latest news from Legacy Medi4!

    Our Picks

    What Is Oil Pulling?

    July 19, 2023

    Top Sweetener Officially Declared a Carcinogen

    July 14, 2023

    Disturbing New Finding Links Cognitive Decline to Dental Hygiene : ScienceAlert

    July 8, 2023

    Type above and press Enter to search. Press Esc to cancel.